<DOC>
	<DOCNO>NCT01524068</DOCNO>
	<brief_summary>This randomize , multi-center , open-label Phase II clinical trial determine efficacy combine plasma exchange ( PEX ) , rituximab , conventional corticosteroid administration , comparison corticosteroid alone , among patient acute Idiopathic Pulmonary Fibrosis ( IPF ) exacerbation . The investigator central hypothesis antibody-mediated autoimmunity play important role IPF exacerbation . The investigator propose test central hypothesis establish efficacy autoantibody removal plasma exchange ( PEX ) , conjunction B-cell depletion rituximab deplete immunoglobulins minimize production , among patient acute IPF exacerbation . The primary goal randomize , multi-center , open-label Phase II clinical trial determine effect combine plasma exchange ( PEX ) , rituximab , conventional corticosteroid administration select , relevant immunological parameter , comparison effect steroids alone , among AE-IPF patient . The investigator anticipate finding lead large incremental trial ( ) determine actual clinical efficacy treatment . A total 40 subject enrol multi-center trial 5 participate medical center .</brief_summary>
	<brief_title>A MultiCenter Study Combined PEX , Rituximab , Steroids Acute Idiopathic Pulmonary Fibrosis Exacerbations</brief_title>
	<detailed_description>This randomize , multi-center , open-label Phase II clinical trial determine efficacy combine plasma exchange ( PEX ) , rituximab , conventional corticosteroid administration , comparison corticosteroid alone , among patient acute IPF exacerbation .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . A diagnosis idiopathic pulmonary fibrosis fulfills American Thoracic Society Consensus Criteria.1 2 . Unexplained worsen development dyspnea hypoxemia within precede 30 day . 3 . Radiographic image show groundglass abnormality and/or consolidation superimpose reticular honeycomb pattern consistent UIP . EXCLUSION CRITERIA 1 . Diagnosis document infection , thromboembolic disease , additional etiology acute lung injury/adult respiratory distress syndrome , congestive heart failure . 2 . Presence active hepatitis B infection . 3 . Coagulopathy define INR &gt; 1.8 , PTT &gt; 2 x control , platelet count &lt; 50K . 4 . Hyperosmolar state diabetic ketoacidosis suggest uncontrolled diabetes mellitus uncontrolled hypertension . 5 . Hemodynamic instability . 6 . History reaction blood product , murinederived product , prior exposure humanmurine chimeric antibody , 7 . History malignancy . 8 . Unwillingness accept blood transfusion . 9 . Unwillingness agree full supportive medical care ( e.g. , intubation ) 2 week enrollment . 10 . Inability unwillingness complete posttreatment surveillance 60 day . 11 . Diagnosis major comorbidities expect interfere subject study participation 28 day . 12 . Treatment &gt; 5 day within precede month &gt; 20 mg prednisone ( equivalent dose corticosteroid ) treatment precede month potent cellular immunosuppressant ( e.g. , cyclophosphamide , methotrexate , mycophenolate , azathiaprine , calcineurin inhibitor , etc . ) unless patient BAL negative opportunistic pathogen ( e.g , Pneumocystis , virus , intracellular organism , mycobacteria , etc. ) . 13 . Current treatment angiotensin convert enzyme inhibitor discontinue and/or substitute another antihypertensive agent ( minimize potential hemodynamic complication PEX ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Acute Idiopathic Pulmonary Fibrosis Exacerbations</keyword>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>IPF</keyword>
</DOC>